Preliminary Efficacy of Growth Hormone Therapy in Children With Congenital HeartDisease and Short Stature: A Six-case Report and Literature Review
- VernacularTitle:生长激素治疗先天性心脏病合并身材矮小患儿初步疗效:6例病例报告并文献复习
- Author:
Xi YANG
1
,
2
;
Siyu LIANG
3
;
Qianqian LI
4
;
Hanze DU
3
;
Shuaihua SONG
3
;
Yue JIANG
3
;
Huijuan MA
1
;
Shi CHEN
3
;
Hui PAN
3
Author Information
- Publication Type:Journal Article
- Keywords: congenital heart disease; short stature; recombinant human growth hormone; growth retardation; congenital malformation
- From: Medical Journal of Peking Union Medical College Hospital 2025;16(3):641-646
- CountryChina
- Language:Chinese
-
Abstract:
Congenital heart disease (CHD) is a congenital malformation resulting from abnormal embryonic development of the heart and great vessels, accounting for approximately 25% of all congenital malformations. Children with CHD are often complicated by short stature. Although surgical treatment can improve their growth and development to a certain extent, some children still experience growth retardation after surgery. Recombinant human growth hormone (rhGH) is the main drug for treating short stature, but its efficacy and safety in the treatment of patients with concomitant CHD warrant further investigation. This article reports six cases of children with CHD and short stature who were treated with rhGH. Through a literature review, we summarize and discuss the therapeutic efficacy, follow-up experiences, and adverse reactions of rhGH treatment, aiming to provide references for clinicians in applying rhGH to treat patients with CHD and short stature.